BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
EPA:BLC - Euronext Paris - Matif - FR0000035370 - Common Stock - Currency: EUR
Taking everything into account, BLC scores 4 out of 10 in our fundamental rating. BLC was compared to 26 industry peers in the Health Care Providers & Services industry. BLC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BLC is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BLC had negative earnings in the past year.
BLC had a positive operating cash flow in the past year.
Of the past 5 years BLC 4 years were profitable.
In the past 5 years BLC always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of -0.14%, BLC is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
BLC has a Return On Equity of -1.13%. This is in the lower half of the industry: BLC underperforms 76.92% of its industry peers.
BLC's Return On Invested Capital of 5.82% is fine compared to the rest of the industry. BLC outperforms 65.38% of its industry peers.
BLC had an Average Return On Invested Capital over the past 3 years of 5.34%. This is in line with the industry average of 5.35%.
The last Return On Invested Capital (5.82%) for BLC is above the 3 year average (5.34%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -1.13% | ||
| ROIC | 5.82% |
ROA(3y)1.29%
ROA(5y)1.7%
ROE(3y)9.6%
ROE(5y)12.13%
ROIC(3y)5.34%
ROIC(5y)5.17%
1.3 Margins
The Operating Margin of BLC (7.22%) is better than 65.38% of its industry peers.
BLC's Operating Margin has improved in the last couple of years.
BLC has a Gross Margin of 66.91%. This is in the better half of the industry: BLC outperforms 76.92% of its industry peers.
BLC's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.22% | ||
| PM (TTM) | N/A | ||
| GM | 66.91% |
OM growth 3Y3.59%
OM growth 5Y6.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.18%
GM growth 5Y6.9%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
Compared to 1 year ago, BLC has less shares outstanding
The number of shares outstanding for BLC remains at a similar level compared to 5 years ago.
BLC has a better debt/assets ratio than last year.
2.2 Solvency
BLC has an Altman-Z score of 1.34. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
BLC has a Altman-Z score (1.34) which is comparable to the rest of the industry.
The Debt to FCF ratio of BLC is 10.96, which is on the high side as it means it would take BLC, 10.96 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 10.96, BLC is doing worse than 73.08% of the companies in the same industry.
A Debt/Equity ratio of 4.30 is on the high side and indicates that BLC has dependencies on debt financing.
BLC has a worse Debt to Equity ratio (4.30) than 88.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.3 | ||
| Debt/FCF | 10.96 | ||
| Altman-Z | 1.34 |
ROIC/WACC1.24
WACC4.71%
2.3 Liquidity
A Current Ratio of 0.97 indicates that BLC may have some problems paying its short term obligations.
BLC has a Current ratio of 0.97. This is in the better half of the industry: BLC outperforms 61.54% of its industry peers.
BLC has a Quick Ratio of 0.97. This is a bad value and indicates that BLC is not financially healthy enough and could expect problems in meeting its short term obligations.
With a decent Quick ratio value of 0.77, BLC is doing good in the industry, outperforming 65.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.97 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
BLC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -107.95%.
The Revenue has been growing slightly by 4.28% in the past year.
Measured over the past years, BLC shows a quite strong growth in Revenue. The Revenue has been growing by 9.55% on average per year.
EPS 1Y (TTM)-107.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.41%
Revenue 1Y (TTM)4.28%
Revenue growth 3Y6.06%
Revenue growth 5Y9.55%
Sales Q2Q%2.49%
3.2 Future
BLC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.38% yearly.
The Revenue is expected to grow by 5.84% on average over the next years.
EPS Next Y-12.79%
EPS Next 2Y6.57%
EPS Next 3Y10.38%
EPS Next 5YN/A
Revenue Next Year7.14%
Revenue Next 2Y6.99%
Revenue Next 3Y6.96%
Revenue Next 5Y5.84%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BLC. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 11.02, the valuation of BLC can be described as reasonable.
BLC's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BLC is cheaper than 76.92% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BLC to the average of the S&P500 Index (22.10), we can say BLC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 11.02 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BLC is valued cheaper than 88.46% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BLC is valued cheaper than 80.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.94 | ||
| EV/EBITDA | 5.61 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.57%
EPS Next 3Y10.38%
5. Dividend
5.1 Amount
No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (3/7/2025, 7:00:00 PM)
25.05
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners10.08%
Inst Owner ChangeN/A
Ins Owners1.58%
Ins Owner ChangeN/A
Market Cap184.37M
Analysts83.33
Price Target29.07 (16.05%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.22
Dividend Growth(5Y)-3.37%
DP-180.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-39.68%
EPS NY rev (3m)-17.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 11.02 | ||
| P/S | 0.35 | ||
| P/FCF | 4.94 | ||
| P/OCF | 1.99 | ||
| P/B | 2.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.61 |
EPS(TTM)-0.12
EYN/A
EPS(NY)2.27
Fwd EY9.07%
FCF(TTM)5.07
FCFY20.23%
OCF(TTM)12.59
OCFY50.27%
SpS71.98
BVpS10.84
TBVpS-18.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -1.13% | ||
| ROCE | 8.87% | ||
| ROIC | 5.82% | ||
| ROICexc | 6.16% | ||
| ROICexgc | 13.22% | ||
| OM | 7.22% | ||
| PM (TTM) | N/A | ||
| GM | 66.91% | ||
| FCFM | 7.04% |
ROA(3y)1.29%
ROA(5y)1.7%
ROE(3y)9.6%
ROE(5y)12.13%
ROIC(3y)5.34%
ROIC(5y)5.17%
ROICexc(3y)5.7%
ROICexc(5y)5.58%
ROICexgc(3y)12.68%
ROICexgc(5y)11.8%
ROCE(3y)8.16%
ROCE(5y)7.93%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y1.85%
ROICexc growth 3Y8.09%
ROICexc growth 5Y5.81%
OM growth 3Y3.59%
OM growth 5Y6.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.18%
GM growth 5Y6.9%
F-Score5
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.3 | ||
| Debt/FCF | 10.96 | ||
| Debt/EBITDA | 3.37 | ||
| Cap/Depr | 87.47% | ||
| Cap/Sales | 10.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.27% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.97 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 1.34 |
F-Score5
WACC4.71%
ROIC/WACC1.24
Cap/Depr(3y)89.47%
Cap/Depr(5y)88.81%
Cap/Sales(3y)10.8%
Cap/Sales(5y)10.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-107.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.41%
EPS Next Y-12.79%
EPS Next 2Y6.57%
EPS Next 3Y10.38%
EPS Next 5YN/A
Revenue 1Y (TTM)4.28%
Revenue growth 3Y6.06%
Revenue growth 5Y9.55%
Sales Q2Q%2.49%
Revenue Next Year7.14%
Revenue Next 2Y6.99%
Revenue Next 3Y6.96%
Revenue Next 5Y5.84%
EBIT growth 1Y4.18%
EBIT growth 3Y9.86%
EBIT growth 5Y16.32%
EBIT Next Year166.67%
EBIT Next 3Y44.02%
EBIT Next 5YN/A
FCF growth 1Y-28.34%
FCF growth 3Y10.22%
FCF growth 5Y6.95%
OCF growth 1Y-12.29%
OCF growth 3Y7.62%
OCF growth 5Y8.72%